Log in
Enquire now
‌

Zymeron Corporation SBIR Phase I Award, March 2022

A SBIR Phase I contract was awarded to Zymeron Corporation in March, 2022 for $167,495.0 USD from the U.S. Department of Defense and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/2237893
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
Zymeron Corporation
Zymeron Corporation
0
Government Agency
U.S. Department of Defense
U.S. Department of Defense
0
Government Branch
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
0
Award Type
SBIR0
Contract Number (US Government)
W911SR-22-P-00120
Award Phase
Phase I0
Award Amount (USD)
167,4950
Date Awarded
March 16, 2022
0
End Date
August 31, 2022
0
Abstract

Bunyaviruses are the largest family of viruses, which composed of more than 300 of members, several family members including Hantaan virus, Sin Nombre virus Rift Valley Fever virus, Severe Fever with Thrombocytopenia Syndrome virus, and Crimean-Congo Hemorrhagic Fever virus are posing significant threats to the warfighters (and civilians as well). Unfortunately, there are no vaccines for human use or antiviral drugs available to prevent or treat infections with any of these viruses. Meanwhile, the great diversity and continuous emergence of new bunyaviral species that cause severe disease make it unfeasible to develop drugs or vaccines for every single virus. As a result, there is an urgent need to develop medical countermeasure such as small molecule therapeutics which exhibits broad activity across the bunyavirus families. Zymeron is developing small molecule inhibitors of the highly conserved Bunyavirus protein that is essential for the viral replication as broad-spectrum therapeutics targeting the Bunyavirales order. In addition, the small molecule inhibitors comply with the Lipinski’s Rule of Five, indicating strong potential as systemic antiviral candidates for oral administration.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Zymeron Corporation SBIR Phase I Award, March 2022

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us